1. ACE2 in pulmonary diseases
   Qing Lin et al, 2023, Angiotensin CrossRef
2. Allicin, an Emerging Treatment for Pulmonary Arterial Hypertension: An Experimental Study
   José L. Sánchez-Gloria et al, 2023, International Journal of Molecular Sciences CrossRef
3. ACE2 improves endothelial cell function and reduces acute lung injury by downregulating FAK expression
   Yixuan He et al, 2024, International Immunopharmacology CrossRef
4. Use of angiotensin‑converting enzyme inhibitors in gynecological cancers: Pathways and mechanisms involved (Review)
   Roland Lengkey et al, 2024, World Academy of Sciences Journal CrossRef
5. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies
   Helen Christou et al, 2022, American Journal of Physiology-Heart and Circulatory Physiology CrossRef
6. The protective mechanism of sevoflurane in pulmonary arterial hypertension via downregulation of TRAF6
   Guan Wang et al, 2024, Toxicology and Applied Pharmacology CrossRef
7. Ubiquitination of angiotensin-converting enzyme 2 contributes to the development of pulmonary arterial hypertension mediated by neural precursor cell–expressed developmentally down-regulated gene 4-Like
   Rui Wang et al, 2024, Respiratory Research CrossRef
8. Angiotensin-Converting Enzyme 2 (ACE2) Signaling in Pulmonary Arterial Hypertension: Underpinning Mechanisms and Potential Targeting Strategies
   Kostas A. Papavassiliou et al, 2023, International Journal of Molecular Sciences CrossRef
9. ACE2 gene polymorphisms are associated with elevated pulmonary artery pressure in congenital heart diseases
   Yang Zi-yang et al, 2023, Gene CrossRef
10. SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension
    Christine Veith et al, 2022, Circulation CrossRef
11. Renal Abscess Caused by Crizotinib: A Rare Case Report
    Zhaojun Wan et al, 2022, Frontiers in Oncology CrossRef